Đang chuẩn bị liên kết để tải về tài liệu:
Bóa cáo y học: "Could CT screening for lung cancer ever be cost effective in the United Kingdom"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Could CT screening for lung cancer ever be cost effective in the United Kingdom? | Cost Effectiveness and Resource Allocation BioMed Central Research Could CT screening for lung cancer ever be cost effective in the United Kingdom David K Whynes Address Professor of Health Economics School of Economics University of Nottingham Nottingham NG7 2RD UK Email David KWhynes - david.whynes@nottingham.ac.uk Open Access Published 26 February 2008 Cost Effectiveness and Resource Allocation 2008 6 5 doi 10.1186 1478-7547-6-5 Received 4 June 2007 Accepted 26 February 2008 This article is available from http www.resource-allocation.eom content 6 l 5 2008 Whynes licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background The absence of trial evidence makes it impossible to determine whether or not mass screening for lung cancer would be cost effective and indeed whether a clinical trial to investigate the problem would be justified. Attempts have been made to resolve this issue by modelling although the complex models developed to date have required more real-world data than are currently available. Being founded on unsubstantiated assumptions they have produced estimates with wide confidence intervals and of uncertain relevance to the United Kingdom. Method I develop a simple deterministic model of a screening regimen potentially applicable to the UK. The model includes only a limited number of parameters for the majority of which values have already been established in non-trial settings. The component costs of screening are derived from government guidance and from published audits whilst the values for test parameters are derived from clinical studies. The expected health gains as a result of screening are calculated by combining published survival data for screened and unscreened cohorts with data from Life